Trial Profile
A Phase I/II Study of Active Immunotherapy With Ad5[E1-,E2b-]-CEA Vaccine in Patients With Advanced or Metastatic Malignancies Expressing CEA
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs ETBX 011 (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Lung cancer; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Etubics Corporation
- 03 Jun 2014 Long-term follow-up results for the cohort of patients with colorectal cancer presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 06 May 2013 Results published in an Etubics Corporation media release.
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.